122 related articles for article (PubMed ID: 18245952)
21. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
22. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
Guerrero J; Santibañez JF; González A; Martínez J
Exp Cell Res; 2004 Jan; 292(1):201-8. PubMed ID: 14720519
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
[TBL] [Abstract][Full Text] [Related]
24. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
[TBL] [Abstract][Full Text] [Related]
25. The feasibility of uPA/uPAR-targeting strategies in cancer treatment.
Sheng S
Cancer Biol Ther; 2008 May; 7(5):660-2. PubMed ID: 18756623
[No Abstract] [Full Text] [Related]
26. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
27. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C; Del Rosso M
Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
Ignar DM; Andrews JL; Witherspoon SM; Leray JD; Clay WC; Kilpatrick K; Onori J; Kost T; Emerson DL
Clin Exp Metastasis; 1998 Jan; 16(1):9-20. PubMed ID: 9502073
[TBL] [Abstract][Full Text] [Related]
29. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
[TBL] [Abstract][Full Text] [Related]
30. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
32. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Bagheri-Yarmand R; Mazumdar A; Sahin AA; Kumar R
Int J Cancer; 2006 Jun; 118(11):2703-10. PubMed ID: 16381000
[TBL] [Abstract][Full Text] [Related]
33. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Guo Y; Higazi AA; Arakelian A; Sachais BS; Cines D; Goldfarb RH; Jones TR; Kwaan H; Mazar AP; Rabbani SA
FASEB J; 2000 Jul; 14(10):1400-10. PubMed ID: 10877833
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
35. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
36. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Wang X; Hou M; Tan L; Sun X; Zhang Y; Li P; Zhu Y
J Cancer Res Clin Oncol; 2005 Feb; 131(2):129-36. PubMed ID: 15490235
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
[TBL] [Abstract][Full Text] [Related]
39. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
40. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]